Therefore, PAR1 may be a promising marker to predict prognosis and make clinical decisions, and anti-PAR1 antibody may be an effective molecule-targeting agent to improve the prognosis of PAR1-expressing breast cancer patients (including HER2-negative cases). This evidence concerns the gene F2R and breast carcinoma.